Comprehensive text highlighting current clinical research in the area of multiple sclerosis. Includes expanded coverage of genetics, neurobiology, pathophysiology, and historical background.Presumably, there was some laxity in the policing of reimbursements by the insurance companies with a good deal of drift at ... on managing difficulties which might arise, such as perceived lack of efficacy, without discontinuing treatment ( Lublin ... It did not take long for a debate to begin on the managed entry of the interferons in continental Europe and the United ... a product licence in late 1995, Avonex in 1997 and Rebif in 1998, the professional analysis was much more measuredanbsp;...
|Title||:||McAlpine's Multiple Sclerosis|
|Author||:||Douglas McAlpine, Alastair Compston|
|Publisher||:||Elsevier Health Sciences - 2005|